4530 Stock Overview
Hisamitsu Pharmaceutical Co., Inc. engages in the research and development, manufacture, purchase, and sale of pharmaceuticals in Japan.
No risks detected for 4530 from our risk checks.
Hisamitsu Pharmaceutical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||JP¥3,890.00|
|52 Week High||JP¥7,750.00|
|52 Week Low||JP¥3,790.00|
|1 Month Change||0.78%|
|3 Month Change||-14.22%|
|1 Year Change||-37.06%|
|3 Year Change||-45.29%|
|5 Year Change||-28.49%|
|Change since IPO||782.09%|
Recent News & Updates
|4530||JP Pharmaceuticals||JP Market|
Return vs Industry: 4530 underperformed the JP Pharmaceuticals industry which returned -11.9% over the past year.
Return vs Market: 4530 underperformed the JP Market which returned 9.3% over the past year.
|4530 Average Weekly Movement||4.3%|
|Pharmaceuticals Industry Average Movement||3.9%|
|Market Average Movement||4.1%|
|10% most volatile stocks in JP Market||8.0%|
|10% least volatile stocks in JP Market||2.2%|
Stable Share Price: 4530 is not significantly more volatile than the rest of JP stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 4530's weekly volatility (4%) has been stable over the past year.
About the Company
Hisamitsu Pharmaceutical Co., Inc. engages in the research and development, manufacture, purchase, and sale of pharmaceuticals in Japan. The company provides analgesic / anti-inflammatory patches; athlete's foot / ringworm remedy products; allergy-only rhinitis drugs; eye drops; high cholesterol improving drugs; acne remedies; cooling sheets; and supporters for knee, waist, elbow, calf and ankle. It also provides cooling sprays; bactericidal antibacterial spray and deodorant spray; ship fixing sheet; adhesive plasters for magnetic products; skin care products; sweat sheet; massage roller gel and oil spray; thermal equipment, and dietary supplements.
Hisamitsu Pharmaceutical Fundamentals Summary
|4530 fundamental statistics|
Is 4530 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|4530 income statement (TTM)|
|Cost of Revenue||JP¥48.88b|
Last Reported Earnings
Aug 31, 2021
Next Earnings Date
Jan 13, 2022
|Earnings per share (EPS)||129.18|
|Net Profit Margin||8.79%|
How did 4530 perform over the long term?See historical performance and comparison
2.2%Current Dividend Yield
Does 4530 pay a reliable dividends?See 4530 dividend history and benchmarks
|Hisamitsu Pharmaceutical dividend dates|
|Ex Dividend Date||Feb 25 2022|
|Dividend Pay Date||May 28 2022|
|Days until Ex dividend||79 days|
|Days until Dividend pay date||171 days|
Does 4530 pay a reliable dividends?See 4530 dividend history and benchmarks
Is Hisamitsu Pharmaceutical undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 4530 (¥3890) is trading below our estimate of fair value (¥7678.8)
Significantly Below Fair Value: 4530 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 4530 is poor value based on its PE Ratio (30.1x) compared to the JP Pharmaceuticals industry average (18.1x).
PE vs Market: 4530 is poor value based on its PE Ratio (30.1x) compared to the JP market (13x).
Price to Earnings Growth Ratio
PEG Ratio: 4530 is poor value based on its PEG Ratio (1.6x)
Price to Book Ratio
PB vs Industry: 4530's PB Ratio (1.2x) is in line with the JP Pharmaceuticals industry average.
How is Hisamitsu Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4530's forecast earnings growth (18.8% per year) is above the savings rate (0.02%).
Earnings vs Market: 4530's earnings (18.8% per year) are forecast to grow faster than the JP market (10.3% per year).
High Growth Earnings: 4530's earnings are forecast to grow, but not significantly.
Revenue vs Market: 4530's revenue (7.5% per year) is forecast to grow faster than the JP market (4.9% per year).
High Growth Revenue: 4530's revenue (7.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4530's Return on Equity is forecast to be low in 3 years time (7.4%).
How has Hisamitsu Pharmaceutical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4530 has high quality earnings.
Growing Profit Margin: 4530's current net profit margins (8.8%) are lower than last year (11.4%).
Past Earnings Growth Analysis
Earnings Trend: 4530's earnings have declined by 10.8% per year over the past 5 years.
Accelerating Growth: 4530's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 4530 had negative earnings growth (-28.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9.3%).
Return on Equity
High ROE: 4530's Return on Equity (4.1%) is considered low.
How is Hisamitsu Pharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: 4530's short term assets (¥206.1B) exceed its short term liabilities (¥31.7B).
Long Term Liabilities: 4530's short term assets (¥206.1B) exceed its long term liabilities (¥17.3B).
Debt to Equity History and Analysis
Debt Level: 4530 has more cash than its total debt.
Reducing Debt: 4530's debt to equity ratio has reduced from 1% to 0.5% over the past 5 years.
Debt Coverage: 4530's debt is well covered by operating cash flow (1157.2%).
Interest Coverage: 4530 earns more interest than it pays, so coverage of interest payments is not a concern.
What is Hisamitsu Pharmaceutical current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 4530's dividend (2.16%) is higher than the bottom 25% of dividend payers in the JP market (1.43%).
High Dividend: 4530's dividend (2.16%) is low compared to the top 25% of dividend payers in the JP market (3.3%).
Stability and Growth of Payments
Stable Dividend: 4530's dividends per share have been stable in the past 10 years.
Growing Dividend: 4530's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (64.8%), 4530's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Mr. Hirotaka Nakatomi serves as the Chief Executive Officer of Hisamitsu Pharmaceutical Co. Inc. Mr. Nakatomi served as the President of Hisamitsu Pharmaceutical Co. Inc. Mr. Nakatomi serves as the Chairma...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Hirotaka's total compensation is reasonable compared to companies of similar size in the JP market.
Compensation vs Earnings: Hirotaka's compensation has been consistent with company performance over the past year.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Hisamitsu Pharmaceutical Co., Inc.'s employee growth, exchange listings and data sources
- Name: Hisamitsu Pharmaceutical Co., Inc.
- Ticker: 4530
- Exchange: TSE
- Founded: 1847
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: JP¥317.961b
- Shares outstanding: 81.74m
- Website: https://www.hisamitsu.co.jp
Number of Employees
- Hisamitsu Pharmaceutical Co., Inc.
- 408, Tashiro Daikan-machi
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/07 15:58|
|End of Day Share Price||2021/12/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.